Po-Yi Chou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Po-Yi Chou has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Chia-Ling Yu
Department of Pharmacy, Chang Gung Memorial Hospital, Taoyuan, Taiwan
3 shared publications - Chih-Sung Liang
Department of Psychiatry, Beitou Branch, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
3 shared publications - Ching-Chi Chi
Department of Dermatology Chang Gung Memorial Hospital, Linkou Main Branch Taoyuan Taiwan
3 shared publications - Li-Huei Chiang
Department of Pharmacy Chang Gung Memorial Hospital, Linkou Taoyuan Taiwan
3 shared publications Tzu-Yu Wang
Department of Applied Cosmetology, Lee-Ming Institute of Technology, New Taipei, Taiwan
3 shared publications- Yu-Kang Tu
Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan; Department of Dentistry, National Taiwan University Hospital, Taipei, Taiwan; Health Data Research Center, National Taiwan University, Taipei, Taiwan
3 shared publications
Latest Publications
- Open Access
- 9 September 2023
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 24 (6) , 1003
Correction to: Authors’ Reply to Chen and Chen: Comment on: “Isotretinoin Exposure and Risk of Inflammatory Bowel Disease: A Systematic Review with Meta-Analysis and Trial Sequential Analysis”
- 9 September 2023
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 24 (6) , 1003
Open AccessCorrection to: Authors’ Reply to Chen and Chen: Comment on: “Isotretinoin Exposure and Risk of Inflammatory Bowel Disease: A Systematic Review with Meta-Analysis and Trial Sequential Analysis”
- 3 April 2023
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 24 (5) , 721-730
Isotretinoin Exposure and Risk of Inflammatory Bowel Disease: A Systematic Review with Meta-Analysis and Trial Sequential Analysis
Background Cases of inflammatory bowel disease (IBD) following isotretinoin use have been reported previously, but whether isotretinoin exposure is associated with IBD has been unclear. Objective The aim was to evaluate whether isotretinoin use is associated with IBD. Methods We performed a systematic review and searched MEDLINE, Embase, and CENTRAL databases from inception to January 27, 2023 for relevant case–control and cohort studies. Our outcome was the pooled odds ratio (OR) for IBD and its two subtypes (Crohn disease and ulcerative colitis) in relation to isotretinoin exposure. We conducted a random-effects model meta-analysis and a sensitivity analysis by excluding low-quality studies. A subgroup analysis was undertaken by including studies considering antibiotic use. A trial sequential analysis (TSA) was performed to test the robustness of the conclusiveness of our results. Results We included eight studies (four case–control and four cohort studies) with a total of 2,522,422 participants. The meta-analysis found no increased odds for IBD among patients receiving isotretinoin (OR 1.01; 95% confidence interval [CI] 0.80–1.27). Nor did the meta-analysis find increased odds for either Crohn disease (OR 0.87; 95% CI 0.65–1.15) or ulcerative colitis (OR 1.27; 95% CI 0.94–1.73) associated with isotretinoin exposure. The sensitivity and subgroup analyses produced similar results. In TSA, the Z-curve reached the futility boundaries when using relative risk reduction thresholds ranging from 5% to 15%. Conclusion This meta-analysis with TSA found no evidence of an association of isotretinoin use with IBD. Isotretinoin should not be withheld because of unnecessary concerns for the development of IBD. PROSPERO registration no CRD42022298886.
- 3 April 2023
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 24 (5) , 721-730
Isotretinoin Exposure and Risk of Inflammatory Bowel Disease: A Systematic Review with Meta-Analysis and Trial Sequential Analysis
Background Cases of inflammatory bowel disease (IBD) following isotretinoin use have been reported previously, but whether isotretinoin exposure is associated with IBD has been unclear. Objective The aim was to evaluate whether isotretinoin use is associated with IBD. Methods We performed a systematic review and searched MEDLINE, Embase, and CENTRAL databases from inception to January 27, 2023 for relevant case–control and cohort studies. Our outcome was the pooled odds ratio (OR) for IBD and its two subtypes (Crohn disease and ulcerative colitis) in relation to isotretinoin exposure. We conducted a random-effects model meta-analysis and a sensitivity analysis by excluding low-quality studies. A subgroup analysis was undertaken by including studies considering antibiotic use. A trial sequential analysis (TSA) was performed to test the robustness of the conclusiveness of our results. Results We included eight studies (four case–control and four cohort studies) with a total of 2,522,422 participants. The meta-analysis found no increased odds for IBD among patients receiving isotretinoin (OR 1.01; 95% confidence interval [CI] 0.80–1.27). Nor did the meta-analysis find increased odds for either Crohn disease (OR 0.87; 95% CI 0.65–1.15) or ulcerative colitis (OR 1.27; 95% CI 0.94–1.73) associated with isotretinoin exposure. The sensitivity and subgroup analyses produced similar results. In TSA, the Z-curve reached the futility boundaries when using relative risk reduction thresholds ranging from 5% to 15%. Conclusion This meta-analysis with TSA found no evidence of an association of isotretinoin use with IBD. Isotretinoin should not be withheld because of unnecessary concerns for the development of IBD. PROSPERO registration no CRD42022298886.